Abstract:Malignant pericardial effusion is one of the serious complications of lung cancer and lack effective treatment methods. The aim of this study is to evaluate the efficacy and safety of radiofrequency hyperthermia combined with chemotherapy for patients with malignant pericardial effusion caused by lung cancer.Fifty-five patients with malignant pericardial effusion caused by lung cancer were divided into hyperthermia combined with chemotherapy group (combined therapy group) and chemotherapy group. The combined therapy group was treated with radiofrequency hyperthermia after the pericardiocentesis and intracavitary injection (cisplatin 20 mg and dexamethasone 5 mg), when patients' general state of health improved, systemic chemotherapy was performed. The chemotherapy group was treated only with intracavitary injection and systemic chemotherapy. Intracavitary chemotherapy was performed for 1-6 times (average 3 times). Hyperthermia was performed twice per week with an average of 6 times following intracavitary and systemic chemotherapy. The temperature of intracavitary was 40.5 °C-41.5 °C for 60 min during the hyperthermia periods. Systemic chemotherapy consists of cisplatin (75 mg/m²) and vinorelbine (50 mg/m²).The complete remission rate (CR) of malignant pericardial effusion was 54.3% and the response rate (RR) was 91.4% in the combined therapy group, while the rates of CR and RR of chemotherapy group were 25.0% and 70.0%, and the differences of CR and RR between the two groups were significant (P<0.05). After treatment, the quality of life improved significantly in both groups, but the combined therapy group had a higher KPS score than in the chemotherapy group (P<0.05). The adverse events associated with the chemotherapy included gastrointestinal toxicity and myelosuppression, and there were no significant differences between the two groups. The main side effects associated with radiofrequency hyperthermia included local skin ache (8.6%) and induration of subcutaneous fat (5.7%).Radiofrequency hyperthermia combined with chemotherapy is effective in treatment of malignant pericardial effusion and can significantly improve the quality of life of patients without increasing the toxicity of chemotherapy, and side effects could be tolerable.

Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer

Intrapericardial Infusion of Etoposide and Cisplatin in Treating Malignant Pericardial Effusion of Non-small Cell Lung Cancer

Clinical Observision of Intrapericardial Drug Through Intraducing the Intrapericardial Indwelling Tube in Patients with Malignant Pericardial Effusion

Clinical Analysis of 50 Caces of Lung Cancer with Pericardial Effusion

Studies of the significance of intercostal arterial infusion in multi-interventional therapy for malignant pleural effusion with pulmonary carcinoma

Efficacy of radiofrequency hyperthermia combined with chemotherapy in treatment of malignant pericardial effusion caused by lung cancer]

Effect of intrapleural perfusion chemotherapy on malignant pleural effusion in patients with non-small cell lung cancer

The heart wraps to place a tube to lead to flow inside the chamber and infuse into agreeable platinum to malignant heart pack the treatment effect that accumulate a liquid

Clinical observation on malignant pleural effusion treated by intrapleural perfusion of carboplatin combined with interleukin-2

Therapeutic Effects of 5-Fluorouracil Sustained-Release Particles in 81 Malignant Pericardial Effusion Patients.

Intrapleural Administration of Cisplatin to Treat Malignant Pleural Effusions in Patients with Non-Small Cell Lung Cancer:The Efficacy and Pharmacokinetics

A Phase I Study of Daily Carboplatin and Simultaneous Accelerated, Hyperfractionated Chest Irradiation in Patients with Regionally Inoperable Non-Small Cell Lung Cancer

Treatment of malignant pericardial effusion caused by pulmonary malignant tumor with catheter drainage of pericardium and intracavitary administration of interleukin Ⅱ

Efficacy and Safety Assessment of Intrathoracic Perfusion Chemotherapy Combined with immunological factor Interleukin-2 in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Cohort Study

The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias

Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients

Effect of the combination of recombinant human endostatin injection and intrapleural hyperthermic perfusion with nadaplatin on treatment efficacy of non-small cell lung cancer complicated with pleural effusion

Curative Effects of Dendritic Cells Combined with Cytokine-Induced Killer Cells in Patients with Malignant Pericardial Effusion

[A case of pericarditis carcinomatosa showing good response following local transfer of lymphokine-activated killer (LAK) cells]

Clinical Observation on Intrapleural Administration of Cisplatin and IL-2 Combined with Systemic Chemotherapy in the Treatment of Malignant Pleural Effusion of Lung Cancer

Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion: a multi-center randomized clinical trial